Drug Discovery
ByMerck Reinforces Oncology Leadership and Therapeutic Area Depth with Robust 2025 Performance
Rahway, NJ – February 2026 – Merck & Co., Inc. reported strong full-year 2025 financial and operational performance,…
AbbVie Accelerates Portfolio-Led Growth in 2025 and Strengthens Its Long-Term Therapeutic Leadership
North Chicago, IL – February 2026 – AbbVie Inc. reported a strong full-year financial performance in 2025, underscoring…
Did Abivax Just Quash Acquisition Rumors by Eli Lilly — and What It Means for Its IBD Breakthrough Asset?
January 26, 2026 — Paris & Global — Abivax SA, the French clinical‑stage biotechnology company, this week publicly dismissed speculation…
Could Sun Pharma’s Bold Bid for Organon Redefine Its U.S. Strategy and Global Footprint?
January 25, 2026 — Mumbai & New York — Sun Pharmaceutical Industries Ltd. (Sun Pharma), India’s largest pharmaceutical company, has…
FDA’s AZ/GSK Biologics Rejections: Data Integrity Wake-Up or R&D Overhaul Catalyst?
FDA rejection letters issued March 3-4, 2026, flagged data integrity lapses in AstraZeneca’s subcutaneous tezepelumab (asthma) and GSK’s…
Acadia’s Daybue CHMP Fight: $2B Rett Revenue at Stake or EMA Brick Wall?
Acadia Pharmaceuticals on March 3, 2026, fired back at CHMP’s rejection of Daybue (trofinetide) expansion into granular symptom…
